Top

Obesity Surgery

Published in:

01-10-2021 | Sleeve Gastrectomy | Original Contributions

Undiagnosed Hyperglycemia Is a Potential Long-term Risk in Metabolic Surgery Patients: 7 Years Follow-up Study

Authors: Amrit Manik Nasta, Ramen Goel, Madhu Goel, Amenah Malek

Published in: Obesity Surgery | Issue 10/2021

Abstract

Introduction

Diabetes is considered to be a surgically correctable illness. As glycemic control begins soon after surgery, the cessation of anti-diabetic medications is early. Patients believe that their diabetes has been “cured” and the need for blood sugar monitoring is forgotten, leading to undiagnosed hyperglycemia and risk of diabetes-related complications.

Aims

To study the effect of bariatric surgery on long-term glycemic control and identify the patients with undiagnosed hyperglycemia.

Methods

All patients with type 2 diabetes who underwent bariatric surgery at our center from January 2012 to December 2013 were included in the study. For each patient, demographic, preoperative, and postoperative data were retrospectively reviewed.

Results

Out of the total 119 patients with diabetes, 91 patients underwent sleeve gastrectomy and 28 underwent Roux-en-Y gastric bypass. Diabetes status at 7 years of follow-up was possible in 53 (44.5%) patients: 44 (48.4%) in SG and 9 (32.2%) in RYGB groups. Overall, complete remission at 7 years was seen in 17 (32.1%) patients and partial remission in 12 (22.6%) patients. Amongst non-remitters (n = 24, 45.3%), 7 (13.2%) patients were on medications with good glycemic control (A1C < 6.5) while 8 (15.1%) patients had poor control (A1C > 6.5) despite ongoing medications. Additionally, 9 (17%) patients had poor glycemic control (A1C > 6.5) and were not receiving any anti-diabetic medications. Patients in whom follow-up A1C was unavailable and their diabetes status remain unknown were 66 (55.5%) at 7 years.

Conclusion

Our study clearly demonstrates high risk of undiagnosed hyperglycemia. Regular long-term follow-up in diabetic patients is even more desirable than amongst patients undergoing bariatric surgery for weight loss alone.

Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–52.CrossRef

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N Engl J Med. 2017;376:641–51.CrossRef

Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity. The SLEEVEPASS Randomized Clinical Trial JAMA. 2018;319(3):241–54.PubMed

Thaler JP, Cummings DE. Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25. https://doi.org/10.1210/en.2009-0367.CrossRefPubMed

Kasama K, Mui W, Lee WJ, et al. IFSO-APC Consensus Statements 2011. Obes Surg. 2012;22:677–84. https://doi.org/10.1007/s11695-012-0610-7.CrossRefPubMed

Nasta AM, Goel R, Dharia S, et al. Weight loss and comorbidity resolution 3 years after bariatric surgery—an Indian perspective. Obes Surg. 2018;28:2712.CrossRef

Goel R, Goel M, Nasta AM, et al. Portion control eating—a determinant of bariatric outcomes. Obes Surg. 2018; https://doi.org/10.1007/s11695-018-3436-0.

Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5. https://doi.org/10.2337/dc09-9036.CrossRefPubMedPubMedCentral

Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. https://doi.org/10.1001/jama.2014.5988.CrossRefPubMed

10.

Coleman KJ, Haneuse S, Johnson E, et al. Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care Aug. 2016;39(8):1400–7. https://doi.org/10.2337/dc16-0194.CrossRef

11.

Aminian A, Brethauer SA, Andalib A, et al. Individualized Metabolic Surgery Score. Ann Surg. 2017;266(4):650–7. https://doi.org/10.1097/SLA.0000000000002407.CrossRefPubMed

12.

Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170–80. https://doi.org/10.1016/j.soard.2016.08.011.CrossRefPubMed

13.

Han Y, Jia Y, Wang H, et al. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: a systematic review and meta-analysis based on 18 studies. Int J Surg. 2020;76:101–10. https://doi.org/10.1016/j.ijsu.2020.02.035.CrossRefPubMed

14.

Sharples AJ, Mahawar K. Systematic review and meta-analysis of randomised controlled trials comparing long-term outcomes of Roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2020;30:664–72. https://doi.org/10.1007/s11695-019-04235-2.CrossRefPubMed

15.

Borgeraas H, Hofsø D, Hertel JK, et al. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2020;21:1–11. https://doi.org/10.1111/obr.13011.CrossRef

16.

Thereaux J, Lesuffleur T, Païta M, et al. Long-term follow-up after bariatric surgery in a national cohort. Br J Surg. 2017;104:1362–71. https://doi.org/10.1002/bjs.10557.CrossRefPubMed

17.

Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73.CrossRef

18.

Aminian A, Vidal J, Salminen P, et al. Late relapse of diabetes after bariatric surgery: not rare, but not a failure. Diabetes Care Mar. 2020;43(3):534–40. https://doi.org/10.2337/dc19-1057.CrossRef

Title: Undiagnosed Hyperglycemia Is a Potential Long-term Risk in Metabolic Surgery Patients: 7 Years Follow-up Study
Authors: Amrit Manik Nasta
Ramen Goel
Madhu Goel
Amenah Malek
Publication date: 01-10-2021
Publisher: Springer US
Keywords: Sleeve Gastrectomy
Bariatric Surgery
Bariatric Surgery
Hyperglycemia
Published in: Obesity Surgery / Issue 10/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-021-05570-z

2024 ASCO Annual Meeting

Springer Medicine

Undiagnosed Hyperglycemia Is a Potential Long-term Risk in Metabolic Surgery Patients: 7 Years Follow-up Study

Abstract

Introduction

Aims

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2021

Prevalence of Peripheral Polyneuropathy Before and After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

Post-bariatric Surgery Outcomes and Complications in Patients with Celiac Disease: a Matched Case-Control Study

Non-operative Management of Obstructing Clot at the Jejunojejunal Anastomosis Site After Laparoscopic Roux-en-Y Gastric Bypass: a Case Report

Impact of Bariatric Surgery on Pulse Wave Velocity as a Measure of Arterial Stiffness: a Systematic Review and Meta-analysis

Effects of a 12-Week Transtheoretical Model–Based Exercise Training Program in Chinese Postoperative Bariatric Patients: a Randomized Controlled Trial

Lisdexamfetamine Pharmacokinetic Comparison Between Patients Who Underwent Roux-en-Y Gastric Bypass and Nonsurgical Controls